iPSC– tag –
-
Xellsmart Secures FDA Fast Track Designation for Parkinson’s iPSC-Derived Cell Therapy, Accelerating CNS Pipeline
Longevity.Technology UK Overview Xellsmart announced its allogeneic, off-the-shelf iPSC-derived cell therapy for Parkinson's disease has received FDA Fast Track designation, expected to accelerate its development program. Specializing in... -
Cellistic CTO Highlights Japanese Conditional Approvals for Cardiac and Parkinson’s iPSC Products, Outlining Path to Commercial-Scale iPSC Cell Therapy Manufacturing
The Medicine Maker UK Overview In an interview with The Medicine Maker, Stefan Braam, CTO of Cellistic, stated that the industry's main focus is the ability to consistently provide iPSC-based cell therapies at commercial scale for large ... -
Chinese iPSC-Derived Cardiomyocyte Therapy Significantly Improves Heart Function in 90% of Heart Failure Patients in Landmark Phase 2 Trial, Published in Nature Medicine
South China Morning Post China Overview A groundbreaking Phase 2 clinical trial conducted by Nanjing Drum Tower Hospital in China reported that 90% of heart failure patients who received iPSC-derived cardiomyocyte injections showed signi... -
DelveInsight Report: Over 12 Companies Enter iPSC-Derived NK Cell Therapy Pipeline, Led by Century Therapeutics and Fate Therapeutics
openPR.com (DelveInsight) India Overview This article provides an overview of a market research report published by DelveInsight, highlighting the rapid growth in the iPSC-derived NK cell therapy pipeline, with over 12 companies developi... -
Bayer Continues Support for BlueRock Therapeutics’ CLARICO Eye Study of iPSC-Derived Photoreceptor Therapy OpCT-001 for Genetic Ocular Disease
TipRanks USA Overview Bayer AG announced continued support for BlueRock Therapeutics' CLARICO eye study, a Phase 1/2a trial evaluating the safety and early efficacy signals of OpCT-001, an iPSC-derived photoreceptor progenitor cell thera... -
BlueRock Therapeutics Advances iPSC-Derived Dopamine Neuron Therapy bemdaneprocel to Phase 3 for Parkinson’s, Demonstrating Significant Motor Improvement in Early Data
RegenMed Review USA Overview BlueRock Therapeutics' iPSC-derived dopamine neuron therapy, bemdaneprocel, is progressing to a Phase 3 trial (exPDite-2) for Parkinson's disease. Earlier 36-month Phase 1 data showed clinically meaningful im... -
Vertex Pharmaceuticals Initiates Phase 3 Trial for iPSC Islet Cell Therapy VX-880 for Type 1 Diabetes, Showing High Rates of Insulin Independence
Facebook (Breakthrough T1D) USA Overview Vertex Pharmaceuticals has launched a Phase 3 clinical trial for zimislecel (VX-880), its stem cell-derived islet cell therapy for severe type 1 diabetes. Prior trials demonstrated remarkable effi... -
Regenerative and Gene Therapies for Rare Diseases Achieve Key Clinical Milestones, Including iPSC for Retinitis Pigmentosa and Gene Therapy for Pediatric Hearing Loss
RegMedNet UK Overview Significant clinical milestones have been reached in regenerative and gene therapies for rare diseases. Sumitomo Pharma America has dosed the first patient in a Phase I/IIa trial of its iPSC-derived cell therapy for... -
China’s Hopstem Biotech Secures Nearly RMB 200 Million in Series C First Close to Advance iPSC Cell Therapy Pipeline Led by hNPC01
Insight, China's Pharmaceutical Industry China Overview China's Hopstem Biotech has completed the first close of nearly RMB 200 million (approximately $27.5 million USD) in Series C funding to advance its iPSC cell therapy pipeline, led ... -
XsellSmart Biopharmaceutical Completes Patient Enrollment in Phase 1 Trial for Universal Cell Therapy XS411 in Parkinson’s-Type Multiple System Atrophy
VCBeat China Overview XsellSmart Biopharmaceutical announced the completion of full participant enrollment in its Phase 1 registrational clinical trial for XS411, a universal cell therapy targeting Parkinson's-type multiple system atroph...
